The FDA granted accelerated approval of a new Alzheimer’s disease medication called Leqembi, made by the pharmaceutical company Eisai Global based on its ability to “may” slow down the progression of cognitive decline early on in the disease. It works by decreasing the number of amyloid plaques in the brain which appear to be the key...Read More
As medical technology allows patients to grow older, we see this technology being used in an inappropriate way to prolong life in a very painful and unsatisfactory way for the patient. The patient’s family is then left with the uncomfortable decision on whether to continue or withdraw care. The most important thing we can do...Read More
